Radotinib
Radotinib (IY-5511) is a small molecule Bcr-Abl tyrosine kinase inhibitor used in research for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), particularly in cases of resistance or intolerance to prior therapies. Its application extends to in vitro and in vivo studies investigating mechanisms of kinase inhibition and overcoming drug resistance in hematological malignancies.
Product Specifications
CAS Number
926037-48-1
Product Name Alternative
BcrAbl, Bcr-Abl1, IY 5511, IY5511, IY-5511, Supect, Radotinib
Field of Research
Cardiovascular Research, Cell Biology, Epigenetics & Chromatin, Pharmacology & Drug Discovery, Signal Transduction, Stem Cell & Developmental Biology
Purity
99.13% (May vary between batches)
Solubility
DMSO:5.31 mg/mL (10.01 mM) ; Ethanol:< 1 mg/mL (insoluble or slightly soluble)
Smiles
Cc1cn (cn1) -c1cc (NC (=O) c2ccc (C) c (Nc3nccc (n3) -c3cnccn3) c2) cc (c1) C (F) (F) F
Molecular Formula
C27H21F3N8O
Molecular Weight
530.5
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Canine IgG1, lambda Isotype Control antibody (HyHEL-10), APC